Drug Profile
Ifabotuzumab - Humanigen
Alternative Names: Anti-EphA3 MAb; Anti-EphA3 monoclonal antibody; Humaneered antibody; IgG1-kappa antibody; IgG1K antibody; KB-004Latest Information Update: 28 Apr 2023
Price :
$50
*
At a glance
- Originator Ludwig Institute for Cancer Research
- Developer Humanigen; Olivia Newton-John Cancer Research Institute
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; EphA3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Acute myeloid leukaemia; Myelodysplastic syndromes; Myelofibrosis
- Preclinical Solid tumours
- No development reported Glioblastoma
Most Recent Events
- 28 Apr 2023 No recent reports of development identified for phase-I development in Glioblastoma in Australia (IV)
- 31 Dec 2022 Preclinical trials in Solid tumours in Australia (IV) (Humanigen pipeline, April 2023)
- 31 Dec 2022 Olivia Newton-John Cancer Research Institute plans a phase Ib dose-escalation and imaging study in Solid tumors (IV) in 2023